Andrew A. Pieper, MD, PhD (IMAGE)
Caption
“Brief P110 treatment during the acute time period after TBI permanently normalized mitochondrial fission / fusion and prevented subsequent harm to the brain, including oxidative damage, blood-brain barrier deterioration, axonal degeneration, and cognitive impairment, 17 months later. This is equivalent to many decades in people,” explained Andrew A. Pieper, MD, PhD, senior author of the study and Director of the Brain Health Medicines Center of the Harrington Discovery Institute at UH.
Credit
UH / CWRU
Usage Restrictions
N/A
License
Original content